[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589073":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":21,"studyPopulation":22,"armGroups":23,"interventions":29,"overallOfficials":17,"centralContacts":34,"locations":44,"responsibleParty":78,"collaborators":82,"id":84,"slug":17,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":17,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":96,"studyType":97,"phases":17,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":47,"whyStopped":17,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Standardized uptake value (SUV)","Standardized uptake value (SUV) of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 for each target lesion of subject or suspected primary tumor or\u002Fand metastasis.","30 days",[14],{"measure":15,"description":16,"timeFrame":12},"Diagnostic efficacy","The sensitivity, specificity and accuracy of α-Syn PET\u002FCT were calculated.",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"COHORT","PROSPECTIVE","Subjects with various α-Syn-related disease patients underwent 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 PET\u002FCT either for an initial assessment or for recurrence detection.\n\nLesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 PET\u002FCT were calculated.","(i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.",[24],{"label":25,"type":17,"description":26,"interventionNames":27},"Single Group Assignment","Each subject receive a single intravenous injection of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 and undergo PET\u002FCT or MRI imaging within the specificed time.",[28],"Diagnostic Test: 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06",[30],{"type":31,"name":32,"description":26,"armGroupLabels":33,"otherNames":17},"DIAGNOSTIC_TEST","18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06",[25],[35,40],{"name":36,"role":37,"phone":38,"phoneExt":17,"email":39},"Ying Wang, MD","CONTACT","+8618702292537","macrossplusvoices@163.com",{"name":41,"role":37,"phone":42,"phoneExt":17,"email":43},"Li Cai, MD","+862260362190","xcl242004@126.com",[45,64],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","350005","China","CN",{"type":54,"coordinates":55},"Point",[56,57],117.28083,31.86389,{"lat":57,"lon":56},[60],{"name":61,"role":37,"phone":62,"phoneExt":17,"email":63},"Qiang Xie, PhD","+8613721108043","ahxq1980@163.com",{"facility":65,"status":47,"city":66,"state":67,"zip":68,"country":51,"countryCode":52,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality","300052",{"type":54,"coordinates":70},[71,72],117.17667,39.14222,{"lat":72,"lon":71},[75,76],{"name":36,"role":37,"phone":38,"phoneExt":17,"email":39},{"name":36,"role":77,"phone":17,"phoneExt":17,"email":17},"SUB_INVESTIGATOR",{"type":79,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Shaobo Yao, PhD","Prof.",[83],{"name":65,"class":6},"100589073",false,"NCT06949670","Alpha-Synuclein PET\u002FCT in Various α-Syn-Related Disease","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated PD (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled α-Syn PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with none PD syndrome; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":94,"type":95},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various α-Syn-related disease patients.",[100,101,102],"Alpha Synuclein Pathology","Alpha-Synuclein","Parkinson Disease",[104,105,101],"PET\u002FCT","MRI","2026-01-27",{"date":108,"type":109},"2026-01-29","ACTUAL",{"date":111,"type":109},"2025-04-01",{"date":113,"type":95},"2028-04-01",{"name":5,"class":6},2]